Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04812106 · ClinicalTrials.gov registry record
Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Terminated
- Registry status
- 8
- Enrollment target
NCT04812106 is a clinical trial that was terminated before completion, run by Ultragenyx Pharmaceutical. The registered enrollment target is 8 participants.
The verdict
NCT04812106 was terminated before completion, sponsored by Ultragenyx Pharmaceutical.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or caregivers) to self-report information.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2022-10-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04812106
The ClinicalTrials.gov registry entry for NCT04812106 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04812106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04812106 about?
NCT04812106 is a clinical study titled "Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program". The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD community, by use of a convenient online platform for participants (or caregivers) to self-report information.
What is the current status of trial NCT04812106?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2022-07-25. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT04812106?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04812106?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.